Researchers at the Toronto General Hospital Research Institute have discovered metformin (the most widely prescribed type 2 diabetic medication) and resveratrol, a compound found in red wine, trigger novel signaling pathways in the small intestine to lower blood sugar.
Biomedical researchers led by Dr. Gang Zheng at Princess Margaret Cancer Centre have successfully converted microbubble technology already used in diagnostic imaging into nanoparticles that stay trapped in tumours to potentially deliver targeted, therapeutic payloads.
Paper in The Lancet Diabetes and Endocrinology shows glucose-lowering therapies pose increased cardiac risk
University Health Network (UHN) has launched a new online resource designed to profile the organization’s experts who work frequently with media.
A new, large-scale Canadian study shows that many adults with traumatic brain injury (TBI) live in a long-term health setting – such as a nursing home- which may not be appropriate for their condition and younger age.
Two internationally acclaimed cancer centres today announced a partnership to accelerate academic and clinical research to advance personalized, targeted therapies against cancer.
A new, first-of-its-kind app has launched to help patients suffering from chronic pain track their opioid use and measure pain levels to assist with the safe use of opioids.
Researchers at the Princess Margaret Cancer Centre are proposing a new model to enable doctors to predict outcomes more accurately for patients with throat cancers specifically caused by Human Papillomavirus (HPV).
An equal group of leading healthcare professionals, patients and caregivers meet to define priorities for Kidney Cancer research and treatment.
The Princess Margaret Cancer Centre, one of the top 5 cancer research centres in the world, received a substantial boost today from TD Bank Group. A $1-million gift will establish the TD Collaboration and Recruitment Fund to recruit post-doctoral students, fellows and other researchers to The Princess Margaret. Recruitment is an integral part of The Princess Margaret’s Billion Dollar Challenge for Personalized Cancer Medicine.
A unique new method to treat a specific group of patients who are at greater risk of rejecting a donor lung, allowing them to live longer after transplant without rejection, has been developed by the Toronto Lung Transplant Program at Toronto General Hospital, University Health Network.
The Princess Margaret Cancer Foundation’s world-leading Road Hockey to Conquer Cancer event is very excited to announce a partnership with VIA Rail Canada that will help expedite the growth of the Toronto-based fundraising event in 2015.
The amount of time a person sits during the day is associated with a higher risk of heart disease, diabetes, cancer, and death, regardless of regular exercise— according to a review study published today in the Annals of Internal Medicine.
JDRF and the Centre for Global eHealth Innovation at the University Health Network (UHN) in Toronto announced publication of interoperability standards for diabetes devices. The work is the result of JDRF Canadian Clinical Trial Network (JDRF CCTN) funding to Dr. Joseph Cafazzo at UHN to pilot the development of standard communication protocols that define how diabetes devices, such as insulin pumps, blood glucose meters, and continuous glucose monitors, communicate with one another and with other devices.
Peter Munk Cardiac Centre unveils platform that targets youth transitioning to adult medical setting
A world-first transitional pain program that aims to stop pain from becoming chronic after surgery is being pioneered at Toronto General Hospital, University Health Network.
Prostate cancer researchers have developed a genetic test to identify which men are at highest risk for their prostate cancer to come back after localized treatment with surgery or radiotherapy.
A world-first pain program that aims to stop pain from becoming chronic after surgery is being pioneered at Toronto General Hospital, University Health Network. Further details will be provided at a media availability session.
The Jesse and Julie Rasch Foundation of Toronto has provided a generous gift of $130,000 to identify agents that specifically target the Hodgkin’s Lymphoma microenvironment.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right